Cover Image
市場調查報告書

肌肉痙攣:開發平台分析

Muscle Spasticity - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 269904
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
肌肉痙攣:開發平台分析 Muscle Spasticity - Pipeline Review, H2 2015
出版日期: 2015年08月12日 內容資訊: 英文 51 Pages
簡介

所謂肌肉痙攣的特徵是指無法好好控制肌肉,肌肉僵硬或不動,造成肌肉無法控制的狀態。症狀有肌肉緊張擴大、反射神經過度活動、疼痛、姿勢異常、骨骼跟關節形成可見的奇特形狀。肌肉痙攣是因為中樞神經傳送到肌肉的訊號失衡造成的。

本報告提供肌肉痙攣的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

肌肉痙攣 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Daewoong Pharmaceutical Co., Ltd.
  • Ipsen S.A.
  • OBI Pharma, Inc.
  • Sanochemia Pharmazeutika AG
  • Sun Pharma Advanced Research Company Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abobotulinumtoxin A
  • baclofen ER
  • NB-2221
  • OBI-858
  • onabotulinumtoxin A
  • tolperisone

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7039IDB

Summary

Global Markets Direct's, 'Muscle Spasticity - Pipeline Review, H2 2015', provides an overview of the Muscle Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Muscle Spasticity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Muscle Spasticity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Muscle Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Muscle Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Muscle Spasticity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Muscle Spasticity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscle Spasticity Overview
  • Therapeutics Development
    • Pipeline Products for Muscle Spasticity - Overview
    • Pipeline Products for Muscle Spasticity - Comparative Analysis
  • Muscle Spasticity - Therapeutics under Development by Companies
  • Muscle Spasticity - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Muscle Spasticity - Products under Development by Companies
  • Muscle Spasticity - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co., Ltd.
    • Ipsen S.A.
    • OBI Pharma, Inc.
    • Sanochemia Pharmazeutika AG
    • Sun Pharma Advanced Research Company Ltd.
  • Muscle Spasticity - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abobotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • baclofen ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NB-2221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBI-858 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolperisone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Muscle Spasticity - Recent Pipeline Updates
  • Muscle Spasticity - Dormant Projects
  • Muscle Spasticity - Discontinued Products
  • Muscle Spasticity - Product Development Milestones
    • Featured News & Press Releases
      • Jul 16, 2015: Ipsen Biopharmaceuticals Announces FDA Approval of Dysport (abobotulinumtoxinA) for Injection in the Treatment of Upper Limb Spasticity in Adults in the United States
      • Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults
      • Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients
      • Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly
      • Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe
      • Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul
      • Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Muscle Spasticity, H2 2015
  • Number of Products under Development for Muscle Spasticity - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Muscle Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Muscle Spasticity - Pipeline by Ipsen S.A., H2 2015
  • Muscle Spasticity - Pipeline by OBI Pharma, Inc., H2 2015
  • Muscle Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H2 2015
  • Muscle Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Muscle Spasticity Therapeutics - Recent Pipeline Updates, H2 2015
  • Muscle Spasticity - Dormant Projects, H2 2015
  • Muscle Spasticity - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Muscle Spasticity, H2 2015
  • Number of Products under Development for Muscle Spasticity - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top